Reconstitution of T-cell Function in AIDS and ARC Patients by Use of the Endogenous, Leukocyte-Derived Immunomodulator, IMREG-1 A
Int Conf AIDS. 1985 Apr 14-17;1:26 Abstract No. S7F Arthur Gottlieb, JL Farmer, A Levine, P Gill, M Flaum, and MS Gottlieb Tulane Medical School and IMREG, Inc., New Orleans, Louisiana; Univ. So. Calif. Med. Center, Los Angeles; Ochsner Foundation Hospital, New Orleans
IMREG-1, a low molecular weight immunomodulator isolated from normal human leukocytes, has previously been reported to augment and accelerate skin test responses in normal human subjects, and to enhance in vitro production of LIF, MIF and interleukin-2 (IL-2) by the human helper T cell subset, suggesting utility of this agent as an immunopotentiator in AIDS. In initial studies, IMREG-1 was shown to augment mitogen-induced IL-2 production by lymphocytes from ARC or AIDS patients in vitro, and to restore skin test responses to tetanus toxoid in some subjects. Based on these observations, the modulator has been administered to 33 AIDS/ARC patients, with subsequent
monitoring of PHA and PWM-induced proliferative responses, as well as PHA-induced IL-2 production by the patients' lymphocytes. Improvement in functional immune parameters has been noted in 64% (21/33) of subjects evaluated, peaking 7-14 days after modulator administration and declining to initial values by days 21-30. The effect of IMREG-1 on PHA-induced IL-2 production appears to be a sensitive index of the in vivo effects of IMREG-1 in AIDS/ARC.
850414
